One Company Aims to Repurpose a Smallpox Vaccine to Battle HIV

(I-Newswire) August 23, 2010 - Researchers from The Wistar Institute recently reported that a human adenovirus called AdHu26, once thought uncommon, is not so rare after all. This could be bad news for scientists eager to use engineered AdHu26 human adenoviruses as vaccines against HIV and other diseases. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before being used as vectors to deliver genes from pathogens, which then stimulate the body to generate an immune response. Yet studies show that a viral vector may be less effective if the vector is based on a type common in a population, because humans will have previously developed immunity to it.

“AdHu26 is considered by some to be rare in nature and thus there should be less pre-existing immunity. Dr. Hildegund Ertl [at Wistar] is claiming this is incorrect at least for certain human populations,” says Mark J. Newman, Ph.D., Vice President of Research and Development at GeoVax Labs, headquartered in Smyrna, Georgia. In its quest for an HIV vaccine, GeoVax has turned for help to a poxvirus vector called Modified Vaccinia Ankara (MVA), originally developed as a safer smallpox vaccine.

“Since we no longer administer smallpox vaccine except to the military and a select group of first responders for the potential use of smallpox by bioterrorists and smallpox has been eliminated from the human population, the vast majority of people are not being exposed to vaccinia viruses, of which MVA is one,” continues Dr. Newman. “Thus there is a lack of pre-existing immunity, at least in people who were born after 1971 when the universal use of the smallpox vaccine was discontinued.”

Because of the difficulty raising antibodies that are capable of totally blocking natural HIV infections, the GeoVax vaccine approach has focused on raising cellular immune responses in addition to antibodies, which together should be better able to block and control the infections than either can alone. The company’s vaccine proteins, which are inactivated proteins from HIV, are expressed in cells of the vaccinated person following administration of genetically engineered DNA vectored vaccines and live viral vector MVA vaccines.

MVA was chosen, in part, because of its safety features but also because a sufficient amount of HIV genetic material can be inserted which supports the production of virus-like particles in cells. These particles mimic immature HIV viruses and present the viral proteins to the immune system in the correct conformation inducing both cellular immune responses and antibodies. Testing using preclinical nonhuman primate models documented the utility of these vectors for inducing the desired types of immune responses. The company believes this novel approach may well succeed where the use of approaches that induce other types of immune responses may fail.
For more information, log on to www.geovax.com

About The Investor Relations Group:
A first-in-class online destination for investors, the public, and media interested in small-cap public companies.

Company Contact Information
The Investor Relations Group
Janet Vasquez
11 Stone Street 3rd floor
10004
Phone : 212-825-3210